At Spinogenix, we are developing first-in-class therapeutics aimed to restore brain synapses – the critical connections between neurons that allow us to think, plan, remember, and control motor functions.
Understanding and restoring these synaptic connections could revolutionize treatments for a variety of neurodegenerative, neurodevelopmental, and neuropsychiatric conditions.
The nervous system, comprising the brain, spinal cord, and nerves, is responsible for your senses, movement, basic bodily functions, learning, and memory. When this system breaks down, as it does in neurodegenerative conditions, the communication signals across brain synapses fail. This breakdown leads to the loss of cognitive and motor functions, profoundly impacting millions of lives.
Spinogenix aims to develop the first-in-class therapies that go beyond managing symptoms to offer the possibility of meaningful restoration of synaptic function. Spinogenix has completed enrollment of the early Phase 2 clinical trials exploring its investigational compounds for the treatment of Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), schizophrenia, and Fragile X Syndrome (FXS), all delivered as once-daily oral tablets designed to restore synaptic function.
Alzheimer’s Disease (AD)
Fully enrolled. The Phase 2 study evaluating the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of tazbentetol in adults with AD is now completed. A US IND for tazbentetol for AD has been cleared.
Amyotrophic Lateral Sclerosis (ALS)
Fully enrolled. The Phase 2 study evaluating the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of tazbentetol in adults with ALS is now completed. A US IND for tazbentetol for ALS has been cleared and Orphan Drug designation granted.
Schizophrenia (SCZ)
Fully enrolled. The Phase 2 study evaluating the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of tazbentetol in adults with SCZ is now completed. A US IND for tazbentetol for SCZ has been cleared.
Fragile X syndrome (FXS)
Fully enrolled. The Phase 2 study evaluating the safety, efficacy, tolerability, pharmacokinetics, and pharmacodynamics of SPG601 in adult men with FXS is now completed. A US IND for SPG601 for Fragile X has been cleared and Orphan Drug and Fast Track designations granted.